Hagan J J, Slade P D, Gaster L, Jeffrey P, Hatcher J P, Middlemiss D N
Neuroscience Research, SmithKline Beecham Pharmaceuticals, Harlow, Essex, UK.
Eur J Pharmacol. 1997 Jul 23;331(2-3):169-74. doi: 10.1016/s0014-2999(97)01055-8.
The selective, brain penetrant, 5-HT(1B/D) (formerly 5-HT(1D beta/alpha)) receptor agonist SKF-99101H (3-(2-dimethylaminoethyl)-4-chloro-5-propoxyindole hemifumarate) (30 mg/kg i.p.) causes a dose related fall in rectal temperature in guinea pigs which previous studies have shown to be blocked by the non-selective 5-HT(1B/D) receptor antagonist GR-127935 (N-[4-methoxy-3-(4-methyl-1-piperazinyl) phenyl]-2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl) [1,1'biphenyl]-4-carboxamide oxalate). The present study shows that the hypothermic response to SKF-99101H is dose-dependently blocked by SB-224289G (1'-methyl-5-(2'-methyl-4'-[(5-methyl-1,2,4-oxadiazol-3-yl)bipheny l-4-yl]carbonyl)-2,3,6,7-tetrahydrospiro[furo[2,3-f]indole-3,4'-pi peridone] hemioxalate) (0.3-10.0 mg/kg p.o.) (ED50 3.62 mg/kg), which is the first compound to be described which is more than 60 fold selective for the 5-HT1B receptor over the 5-HT1D receptor. SB-216641A (N-[3-(2-dimethylamino) ethoxy-4-methoxy-phenyl] 2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)-(1,1'-biphenyl)-4-car boxamide hydrochloride) (0.6-20.0 mg/kg i.p.), which is somewhat less selective (30 fold) for the 5-HT1B receptor over the 5-HT1D receptor had a similar effect (ED50 4.43 mg/kg). The brain penetrant 5-HT1D selective receptor antagonist, BRL-15572 (4-(3-chlorophenyl)-alpha-(diphenylmethyl)-1-piperazineethanol+ ++ dihydrochloride) (0.3-100.0 mg/kg i.p.) was inactive. When administered alone neither BRL-15572 (0.1-10 mg/kg i.p.) nor SB-224289G (2.2-22 mg/kg p.o.) had an effect on body temperature. These data demonstrate that 5-HT1B (formerly 5-HT(1D beta)) and not 5-HT1D (formerly 5-HT(1D alpha)) receptors mediate the hypothermic response to SKF-99101H (30 mg/kg i.p.) in guinea pigs. The compounds described are useful pharmacological tools for distinguishing responses to 5-HT1B and 5-HT1D receptors.
选择性、可穿透血脑屏障的5-HT(1B/D)(原5-HT(1Dβ/α))受体激动剂SKF-99101H(3-(2-二甲基氨基乙基)-4-氯-5-丙氧基吲哚半富马酸盐)(腹腔注射30毫克/千克)可使豚鼠直肠温度呈剂量依赖性下降,此前的研究表明,非选择性5-HT(1B/D)受体拮抗剂GR-127935(N-[4-甲氧基-3-(4-甲基-1-哌嗪基)苯基]-2'-甲基-4'-(5-甲基-1,2,4-恶二唑-3-基)[1,1'-联苯]-4-甲酰胺草酸盐)可阻断这种下降。本研究表明,SB-224289G(1'-甲基-5-(2'-甲基-4'-[(5-甲基-1,2,4-恶二唑-3-基)联苯-4-基]羰基)-2,3,6,7-四氢螺[呋喃[2,3-f]吲哚-3,4'-哌啶酮]半草酸盐)(口服0.3 - 10.0毫克/千克)(半数有效剂量为3.62毫克/千克)可剂量依赖性地阻断对SKF-99101H的低温反应,SB-224289G是首个被描述的对5-HT1B受体的选择性比对5-HT1D受体高60倍以上的化合物。SB-216641A(N-[3-(2-二甲基氨基)乙氧基-4-甲氧基苯基]2'-甲基-4'-(5-甲基-1,2,4-恶二唑-3-基)-(1,1'-联苯)-4-甲酰胺盐酸盐)(腹腔注射0.6 - 20.0毫克/千克)对5-HT1B受体的选择性比对5-HT1D受体略低(30倍),也有类似作用(半数有效剂量为4.43毫克/千克)。可穿透血脑屏障的5-HT1D选择性受体拮抗剂BRL-15572(4-(3-氯苯基)-α-(二苯甲基)-1-哌嗪乙醇二盐酸盐)(腹腔注射0.3 - 100.0毫克/千克)无活性。单独给药时,BRL-15572(腹腔注射0.1 - 10毫克/千克)和SB-224289G(口服2.2 - 22毫克/千克)对体温均无影响。这些数据表明,在豚鼠中,介导对SKF-99101H(腹腔注射30毫克/千克)低温反应的是5-HT1B(原5-HT(1Dβ))受体而非5-HT1D(原5-HT(1Dα))受体。所述化合物是区分对5-HT1B和5-HT1D受体反应的有用药理学工具。